go to contents

Ablevia biotech GmbH

Back to list

Facts

Founded
2018
Staff
4
Organization type
RDM biotech/pharma
Region
Vienna
Focus
human health

Profile

Ablevia develops a new class of infusible therapeutics to selectively remove harmful and disease-causing antibodies. These therapeutics can be readily adapted to target unwanted antibodies in rare diseases or in conditions with unmet clinical needs. Founded in 2018 at the Vienna Biocenter Campus, Ablevia focuses on IP generation and preclinical research and development.

R&D:Ablevia focusses on research and development of therapeutics for the selective removal of disease-causing and harmful anitbodies in autoimmune diseases or neutralizing anti-drug anitbodies.

Similar companies in RDM biotech/pharma

Tridem Bioscience GmbH

Organization type
RDM biotech/pharma
Region
Vienna
Focus
human health
Details

Allcyte GmbH

Organization type
RDM biotech/pharma
Region
Vienna
Cluster
LISAvienna
Focus
human health
Details

Phoenestra GmbH

Organization type
RDM biotech/pharma
Region
Upper Austria
Cluster
Medical Technology Cluster
Focus
human health
Details

EBEWE Pharma Ges.m.b.H. Nfg.KG

Organization type
RDM biotech/pharma
Region
Upper Austria
Focus
human health
Details

Contact

Maria-Jacobi-Gasse 1
1030 Wien
Vienna

Contact:
Email: office@ablevia.com
Website